GPP
BCAB

Great Point Partners’s BIOATLA INC BCAB Stock Holding History

Great Point Partners’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,286
Closed -$17M – 32
2021
Q4 		$17M Buy
17,286
+406
+2% +$519K 3.77% 7
2021
Q3 		$24.8M Buy
+16,880
New +$32.9M 5.79% 4

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Great Point Partners's BCAB Position: Q1 2022 in Review

Great Point Partners sold out of BIOATLA INC (BCAB) in Q1 2022, closing a stake of 17,286 shares — an estimated $17M sold.

Great Point Partners first reported a position in BCAB in Q3 2021 and held it in 2 quarters. The position peaked at $24.8M in Q3 2021. 97 funds tracked by Wall St. Rank hold BCAB as of Q1 2022.

  • Great Point Partners reported no remaining BIOATLA INC position as of Q1 2022 after selling out during the quarter.
  • Great Point Partners sold 17,286 BIOATLA INC shares in Q1 2022, an estimated $17M.
  • Great Point Partners first reported a position in BIOATLA INC in Q3 2021 and held it in 2 quarters.
  • Great Point Partners's BIOATLA INC position peaked at $24.8M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held BIOATLA INC as of Q1 2022.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.